VCEL (VCEL) Stock Analysis
Verdict: HOLD
MACI adoption fuels rare biopharma profitability, but a trailing P/E of 86x leaves tight safety margins if growth slows.
Investment score: 59/100
Vericel offers verified commercial traction with MACI and Epicel, but a high P/E of 86.0x and recent executive insider selling justify a cautious HOLD stance.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| SRPT | -14.24 | 1.41 | 1.10 | -180.95 | — | -0.07 |
| VRDN | -6.19 | 3.56 | 34.80 | -6.94 | — | -5.44 |
| KOD | -7.96 | 34.18 | 0.00 | -9.35 | — | 0.00 |
| AGIO | -4.80 | 1.95 | 20.44 | -4.66 | — | -4.18 |
| ZBIO | -3.33 | 8.18 | 2021.85 | -4.84 | — | -484.38 |